CLL-623: Outcomes of Patients With Concurrent Chronic Lymphocytic Leukemia and Non-Small Cell Lung Carcinoma

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, and lung carcinoma is the second most common cause of cancer in adults. Limited data are available on clinical and treatment outcomes of patients with concurrent CLL and non-small cell lung carcinoma (NSCLC). A single-center retrospective analysis was conducted of all patients at Moffitt Cancer Center diagnosed with both CLL and NSCLC between January 2001 and December 2023. The primary endpoints were estimated 5-year overall survival (OS) and progression-free survival (PFS), which were calculated using the Kaplan-Meier method. Of 38 patients identified, the majority were male (52.6%) and White (92.1%) patients. In our cohort, most patients were smokers (73.7% past and 10.5% current) and had a history of smoking ≥20 pack years (65.8%). Median age at diagnosis was 62 years for CLL and 69.5 years for NSCLC. For CLL, genomic abnormalities included unmutated IGHV (39.5%), del13q (39.5%), del11q (21.1%), trisomy 12 (21.1%), and del17p (5.3%). For NSCLC, various histologies detected included adenocarcinoma (76.3%), squamous cell carcinoma (13.2%), and others (7.9%). Notable molecular mutations include TP53 (26.3%), KRAS (15.8%), EGFR (10.5%), BRA (10.5%), ATM (10.5%), and ALK (10.5%). Additionally, 14 patients had a third malignancy. The estimated 5-year OS was 46% (95% CI, 32–66) and PFS was 44% (95% CI, 30–64). On comparison, median OS and median PFS was higher in females compared with males (121.8 vs 45.1 months and 52.6 vs 44.6 months, respectively) and patients with history of smoking <20 pack years compared with ≥20 pack years (121.6 vs 52.6 months and 121.8 vs 41.8 months, respectively), but the results did not reach statistical significance. Older age (≥60 years), being male, and smoking are common risk factors for development of both CLL and NSCLC. Most patients with NSCLC were diagnosed with adenocarcinomas with TP53 mutations, whereas most CLL patients were IGHV unmutated and TP53 wildtype. Patients with concurrent CLL and NSCLC are at a higher risk for development of third primary malignancies. Encore abstract originally published in ASCO 2025 online.